Meta‐analysis of the immunogenicity of standard and booster SARS‐CoV‐2 vaccination in patients with chronic liver disease and post‐liver transplantation DOI Creative Commons

Wen‐Xin Wang,

Jitao Wang, Jia Rui

et al.

Portal hypertension & cirrhosis, Journal Year: 2023, Volume and Issue: 2(2), P. 61 - 77

Published: June 1, 2023

Abstract Aims Patients with liver disease may exhibit higher infection rates and mortality from coronavirus 2019 (COVID‐19) than healthy individuals, vaccination against severe acute respiratory syndrome 2 (SARS‐CoV‐2) is an effective prevention strategy. This meta‐analysis aimed to assess the effectiveness safety of SARS‐CoV‐2 vaccines in patients chronic (CLD) post‐liver transplantation (LT). Methods The PubMed, Embase, Cochrane databases were searched. A random‐effects model was used determine seropositivity antibodies, odds ratio (OR) compared controls (HC), risk (RR) between booster standard regimen, rate adverse reactions (ADR). Results In regimen analysis, 17 controlled articles included for six ADR analysis. pooled antibodies CLD post‐LT 93.3% (95% confidence interval [CI]: 89.0%–97.6%) 69.1% CI: 63.0%–75.3%), respectively. Both lower those HC ( p < 0.001). differences remained significant after sorting by detection interval, vaccine type, antibody or type. LT recipients showed much (69.1% vs. 93.3%) (OR: 0.055). total 24.0% 16.2%–31.8%). 11 prospective studies enrolled, dose increased 27% (RR: 1.27, 95% 1.15–1.41, Conclusion can gain protection COVID‐19 vaccines, demonstrating a potentially weaker immunogenic response HC. Booster compensate this deficiency. Therefore, should be prioritized receiving vaccine.

Language: Английский

Immunogenicity of COVID-19 vaccines in patients with cirrhosis: A meta-analysis DOI Creative Commons

Lichen Ouyang,

Gang Lei,

Yeli Gong

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: March 11, 2024

The immunogenicity of COVID-19 vaccines in patients with liver cirrhosis remains largely unknown. purpose this meta-analysis was to investigate the and compare humoral cellular immune responses following complete vaccination between healthy controls. A systematic literature search conducted PubMed, EMBASE, Web Science from 1 January 2020 22 August 2023. Sixteen studies 2127 were included. pooled seroconversion rate 92.4% (95% CI, 86.2%–96%, I2 = 90%) significant between-study heterogeneity. Moreover, elicited a higher response compensated as compared decompensated (RR 1.069, 95% 1.011–1.131, 17%, p .019). Additionally, 10 included for comparison analysis results showed that slightly lower controls 0.972, 0.955–0.989, 66%, .001). Meanwhile, RR vs. 0.678 0.563–0.817, 0, < .0001). Our demonstrated diminished cirrhosis. Patients particularly who have completed full-doses should receive continuous attention preemptive measures.

Language: Английский

Citations

1
Analysis of neutralizing antibodies to COVID-19 inactivated or subunit recombinant vaccines in hospitalized patients with liver dysfunction DOI Creative Commons
Hu Li, Shiyin Li, Pan Xu

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Jan. 18, 2023

The neutralizing antibodies (NAbs) response after COVID-19 vaccination liver dysfunction is unclear. In this study, we evaluated the NAbs in hospitalized patients suffering from dysfunction. cross-sectional study with longitudinal follow-up, enrolled eligible and healthy volunteers full-course vaccination. Blood samples were collected for testing at time of admission treatment. Multiple regression analysis to assess independent risk factors affecting response. A total 137 134 controls (HC) enrolled. Both seropositivity (65.7% vs 80.6%, p<0.01) titer (3.95 4.94 log2 AU/ml, p<0.001) significantly lower than that HC. decrease antibody was faster After adjusting potential confounding factors, males (odds ratio [OR]: 0.17; 95% confidence interval [CI]: 0.06, 0.46; severe damage (OR: 0.30; CI: 0.12, 0.71; associated reduction probability multiple analysis. Males (β =-1.18; -1.73,-0.64) chronic diseases =-1.45; -2.13, -0.76) titers. 26 failure, both (53.8% 84.6%, p<0.05) (3.55 4.32 did not but increased artificial plasmapheresis. inactivated or subunit recombinant vaccines waning Moreover, male sex, injury have an poor responses.

Language: Английский

Citations

3
Durability of immune response after SARS-CoV-2 vaccination in patients with chronic liver disease DOI Creative Commons

Ruixin Song,

Chao Yang, Qianqian Li

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: June 15, 2023

Aim The present study aimed to evaluate the durability of immune response after basic and booster immunization with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients chronic liver disease (CLD). Methods Patients CLD complete or SARS-CoV-2 were included this study. Based on vaccination situation, they divided into immunity group (Basic) (Booster), which then subdivided four groups according time interval from completion serological specimen collection. positive rates antibody titers novel neutralizing (nCoV NTAb) spike receptor-binding domain S-RBD) analyzed. Results A total 313 enrolled study, including 201 Basic 112 Booster. nCoV NTAb S-RBD within 30 days completing 80.4% 84.8%, respectively, but decreased rapidly extension time, only 29% 48.4% remained for S-RBD, 120 immunization. Within immunization, increased 29.0% at end 95.2% 90.5%, maintained a high level (defined as rate &gt;50%) until when still 79.5% 87.2%, respectively. After turn negative was 169 days, significantly prolonged 266 329 Conclusion It is safe effective vaccines. further improved prolonged.

Language: Английский

Citations

3
Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases DOI Creative Commons
Yongmei Liu, Jianhua Lu, Haoting Zhan

et al.

Virologica Sinica, Journal Year: 2023, Volume and Issue: 38(5), P. 723 - 734

Published: July 22, 2023

Chronic liver disease (CLD) entails elevated risk of COVID-19 severity and mortality. The effectiveness the booster dose inactivated SARS-CoV-2 vaccine in stimulating antibody response CLD patients is unclear. Therefore, we conducted a cross-sectional study involving 237 adult 170 healthy controls (HC) to analyze neutralizing antibodies (NAbs) against prototype BA.4/5 variant, anti-receptor binding domain (RBD) IgG, total anti-SARS-CoV-2 antibodies. Serum levels antibodies, anti-RBD IgG inhibition efficacy NAbs were significantly after compared with pre-booster dose, but relatively lower than those HCs. Induced humoral responses decreased over time vaccination. neutralization efficiency serum increased remained below threshold. All four including BA.4/5, severe non-severe CLD. After shot, age last factors for seropositivity NAb patients. Additionally, white blood cell counts hepatitis B core protective factors, was factor associated Overall, our data uncovered that improved peaked at 120 days vaccines. excepting declined peak. exhibited impaired immunologic vaccination weakened which hindered effect shot Omicron prevalence. Cellular immune should be further evaluated determine optimal regimen

Language: Английский

Citations

3
Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant DOI Creative Commons
Gautam Mehta, Antonio Riva, María Pilar Ballester

et al.

Hepatology Communications, Journal Year: 2023, Volume and Issue: 7(11)

Published: Oct. 18, 2023

Background: Vaccine hesitancy and lack of access remain major issues in disseminating COVID-19 vaccination to liver patients globally. Factors predicting poor response risk breakthrough infection are important data target booster vaccine programs. The primary aim the current study was measure humoral responses 2 doses vaccine. Secondary aims included determination factors infection. Methods: Biomarkers cirrhosis And post-Liver Transplantation is a prospective, multicenter, observational case-control study. Participants were recruited at 4–10 weeks following first second [n = 325; 94% messenger RNA (mRNA) 6% viral vaccine], autoimmune disease (AILD) (n 120; 77% mRNA 23% vaccine), post-liver transplant (LT) 146; 96% 3% healthy controls 51; 72% mRNA, 24% 4% heterologous combination). Serological end points measured, regarding SARS-CoV-2 collected. Results: After adjusting by age, sex, time sample collection, anti-Spike IgG levels lowest post-LT compared ( p < 0.0001), AILD control 0.002). reduced older Child-Turcotte-Pugh B/C, elevated IL-6 cirrhosis; non-mRNA AILD; coronary artery disease, use mycophenolate dysregulated B-call activating factor, lymphotoxin-α LT. Incident occurred 6.6%, 10.6%, 7.4%, 15.6% cirrhosis, AILD, post-LT, control, respectively. only independent factor low albumin level. Conclusions: LT present In associated with stage systemic inflammation,

Language: Английский

Citations

3
SARS-CoV-2 Vaccine Uptake among Patients with Chronic Liver Disease: A Cross-Sectional Analysis in Hebei Province, China DOI Creative Commons
Yongmei Liu,

Wenfang Yuan,

Haoting Zhan

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(8), P. 1293 - 1293

Published: July 28, 2023

Chronic liver disease (CLD) patients have higher mortality and hospitalization rates after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aimed to explore SARS-CoV-2 vaccine perceptions, side effects, factors associated nonvaccination attitudes toward fourth-dose among CLD patients. The differences between vaccinated unvaccinated groups 1491 the risk status were analyzed. In total, 1239 immunized against SARS-CoV-2. a high level of trust in government clinicians likely follow their recommendations for vaccination. Reasons reported mainly concerns about vaccines affecting ongoing treatments fear adverse events. However, only 4.84% mild effects. Risk influencing included being older age, having cirrhosis, receiving treatments, no knowledge considerations not doctors' positive advice on Furthermore, 20.6% completely participants refused fourth dose because they concerned effects believed that complete was sufficiently protective. Our proved safe findings suggest governments health workers should provide more vaccination information customize strategies improve coverage enhance protection population.

Language: Английский

Citations

2
Efficacy, immunogenicity, and safety of COVID-19 vaccines in individuals with liver cirrhosis: a rapid review and meta-analysis DOI Creative Commons
Faranak Salajegheh, Mohammad Rezaei Zadeh Rukerd, Mohsen Nakhaie

et al.

Clinical and Experimental Vaccine Research, Journal Year: 2024, Volume and Issue: 13(2), P. 83 - 83

Published: Jan. 1, 2024

The emergence of coronavirus disease 2019 (COVID-19) vaccines has been a remarkable advancement. However, the efficacy, immunogenicity, and safety these in individuals with liver cirrhosis require careful evaluation due to their compromised immune status potential interactions underlying disease. present study aimed evaluate efficacy COVID-19 patients. In study, we searched international databases, including Google Scholar, PubMed, Scopus, Embase, Web Science. search strategy was carried out by using keywords MeSH (Medical Subject Headings) terms. STATA ver. 15.0 (Stata Corp., USA) used analyze data statistically. analysis performed random-effects model. We also chi-square test I

Language: Английский

Citations

0
Dynamic Humoral Immune Response to Primary and Booster Inactivated SARS-CoV-2 Vaccination in Patients with Cirrhosis DOI Open Access
Qian Zhu, Lu Wang, Xiaoxiao Hu

et al.

Journal of Clinical and Translational Hepatology, Journal Year: 2023, Volume and Issue: 11(7), P. 1476 - 1484

Published: Aug. 25, 2023

aim was to determine the im

Language: Английский

Citations

1
Immunogenicity assessment of elder hepatocellular carcinoma patients after inactivated whole-virion SARS-CoV-2 vaccination DOI Creative Commons
Ruyun Gao,

Cuiling Zheng,

Mengwei Yang

et al.

Expert Review of Vaccines, Journal Year: 2023, Volume and Issue: 22(1), P. 1102 - 1113

Published: Oct. 25, 2023

Research on immunogenicity after 3rd SARS-CoV-2 vaccine in elder hepatocellular carcinoma (HCC) was limited. This study aimed to investigate the efficacy and influencing factors of inactivated HCC.We assessed total antibodies, anti-RBD IgG, neutralizing antibodies (NAb) toward wild type (WT) as well BA.4/5 304 uninfected HCC, 147 matched healthy control (HC), 53 infected all aged over 60 years. The levels were compared period 7-90, 91-180, >180 days 2nd or vaccination, respectively.HCC had lower seropositivity than HC dose (total 64% vs. 92%, P < 0.0001; 50% 77%, 0.0001). But can efficaciously close gap 96% 100%, = 0.1212; IgG: 87% 87%, > 0.9999). Booster effect persist HCC (2nd 3rd: 0.60 3.20, 13.86 68.85, WT NAb, 11.70 22.47, Vaccinated more evident humoral responses unvaccinated ones infection antibodies: 3.85 910.92 NAb: 96.09 86.53 5.59, 0.0001).Our findings highlight booster protective role dose. Our results could provide a theoretical foundation for informing decisions regarding vaccination HCC.

Language: Английский

Citations

1
COVID-19 Vaccination in Liver Cirrhosis: Safety and Immune and Clinical Responses DOI Creative Commons

Inês Canha,

Mário Jorge Silva,

Maria Azevedo Silva

et al.

GE Portuguese Journal of Gastroenterology, Journal Year: 2023, Volume and Issue: 31(5), P. 325 - 337

Published: Nov. 15, 2023

Three years after the beginning of SARS-CoV-2 pandemic, safety and efficacy COVID-19 vaccination in liver cirrhosis (LC) patients remain controversial. We aimed to study safety, immunological, clinical responses LC vaccination.

Language: Английский

Citations

1